Table 4 overview of trial results for all studied prophylactic agents in both episodic and chronic mgiraine
| Â | Â | MMD reduction (range) | N | RCTs | negative RCTs | dropouts verum, % (range) | dropouts placebo, % (range) | dropouts verum minus placebo, % |
|---|---|---|---|---|---|---|---|---|
EM | CGRP mAb | 1.9 (1.1-3,0) | 4632 (1852) | 14 (9) | 0 | 2 (0-4) | 2 (0-3) | 0 |
candesartan | 0.9 (0.6-1.2) | 132 | 2 | 0 | 2 (1-2) | 0 (0-0) | 2 | |
topiramate | 1.2 (0.7-1.6) | 1433 (577) | 8 (4) | 1 | 22 (7-35) | 9 (0-12) | 14 | |
valproate | 1.7 (1.3-2.6) | 436 (235) | 6 (3) | 0 | 12 (3-19) | 5 (0-9) | 7 | |
beta-blockers | 0.9 (0.6-2.1) | 1035 (349) | 22 (4) | 0 | 6 (0-20) | 3 (0-10) | 3 | |
amitriptyline | 1.1 | 308 (59) | 3 (1) | 1 | 11 (9-12) | 6 (3-7) | 5 | |
CM | topiramate | 1.8 (1.5-3.7) | 211 (197) | 3 (2) | 0 | 12 (7-19) | 6 (0-11) | 6 |
CGRP mAb | 2.2 (1.7-2.6) | 3191 (1592) | 7 | 0 | 1 (0-5) | 1 (0-2) | 0 | |
onabotulinumtoxinA | 2.0 (1.5-2.4) | 688 | 2 | 1 | 3 (2-3) | 1 (0-2) | 2 |